Eric Ruderman

4.6k total citations · 1 hit paper
84 papers, 2.9k citations indexed

About

Eric Ruderman is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Eric Ruderman has authored 84 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Rheumatology, 26 papers in Immunology and 20 papers in Hematology. Recurrent topics in Eric Ruderman's work include Rheumatoid Arthritis Research and Therapies (55 papers), Spondyloarthritis Studies and Treatments (24 papers) and Systemic Lupus Erythematosus Research (21 papers). Eric Ruderman is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (55 papers), Spondyloarthritis Studies and Treatments (24 papers) and Systemic Lupus Erythematosus Research (21 papers). Eric Ruderman collaborates with scholars based in United States, Australia and Germany. Eric Ruderman's co-authors include Christopher T. Ritchlin, Ernest Choy, Renee Perdok, Dafna D. Gladman, Philip J. Mease, Mark Weinberg, John T. Sharp, Serge Steinfeld, P A Ory and Richard M. Pope and has published in prestigious journals such as The Lancet, The Journal of Infectious Diseases and Annals of the Rheumatic Diseases.

In The Last Decade

Eric Ruderman

81 papers receiving 2.8k citations

Hit Papers

Adalimumab for the treatment of patients with moderately ... 2005 2026 2012 2019 2005 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial
    2005 702 citations Philip J. Mease, Dafna D. Gladman et al. Arthritis & Rheumatism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Ruderman United States 27 1.6k 1.2k 773 476 284 84 2.9k
Mitsumasa Kishimoto Japan 28 1.8k 1.1× 1.1k 0.9× 803 1.0× 177 0.4× 186 0.7× 162 2.9k
Andrew J.K. Östör United Kingdom 31 1.9k 1.2× 982 0.8× 898 1.2× 390 0.8× 607 2.1× 131 3.8k
Philippe Gaudin France 32 2.3k 1.4× 644 0.6× 829 1.1× 408 0.9× 220 0.8× 148 3.4k
Ennio Giulio Favalli Italy 34 2.2k 1.4× 915 0.8× 864 1.1× 234 0.5× 219 0.8× 138 3.5k
Frank Behrens Germany 27 2.5k 1.5× 2.4k 2.1× 1.4k 1.8× 272 0.6× 199 0.7× 178 3.7k
Joung-Liang Lan Taiwan 17 1.9k 1.2× 1.3k 1.1× 196 0.3× 487 1.0× 281 1.0× 24 3.2k
Patrick Verschueren Belgium 25 1.7k 1.0× 434 0.4× 480 0.6× 383 0.8× 258 0.9× 178 2.5k
Jeffrey D. Greenberg United States 41 4.0k 2.5× 1.5k 1.3× 1.3k 1.7× 529 1.1× 510 1.8× 144 5.4k
C. Daïen France 27 1.1k 0.7× 572 0.5× 322 0.4× 208 0.4× 224 0.8× 77 2.2k
Elena Myasoedova United States 25 2.4k 1.5× 448 0.4× 433 0.6× 316 0.7× 371 1.3× 102 3.5k

Countries citing papers authored by Eric Ruderman

Since Specialization
Citations

This map shows the geographic impact of Eric Ruderman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Ruderman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Ruderman more than expected).

Fields of papers citing papers by Eric Ruderman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Ruderman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Ruderman. The network helps show where Eric Ruderman may publish in the future.

Co-authorship network of co-authors of Eric Ruderman

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Ruderman. A scholar is included among the top collaborators of Eric Ruderman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Ruderman. Eric Ruderman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Greene, George J., Jennifer L. Beaumont, Karen Kaiser, et al.. (2023). Integrating PROMIS Measures in a Treat-to-Target Approach to Standardize Patient-Centered Treatment of Rheumatoid Arthritis. The Journal of Rheumatology. 50(8). 1002–1008. 5 indexed citations
2.
Arneson, Laura C., et al.. (2021). Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis. ImmunoTargets and Therapy. Volume 10. 333–342. 31 indexed citations
3.
Nash, Peter, Pascal Richette, Laure Gossec, et al.. (2021). Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis. Lara D. Veeken. 61(8). 3257–3268. 17 indexed citations
4.
Huizinga, T., Peter A. Nigrović, Eric Ruderman, & Hendrik Schulze‐Koops. (2011). Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation: Commentary. 9(2). 71–72. 1 indexed citations
5.
Huizinga, T., Peter A. Nigrović, Eric Ruderman, & Hendrik Schulze‐Koops. (2011). Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS): Commentary. 9(3). 1 indexed citations
6.
Huizinga, T., Peter A. Nigrović, Eric Ruderman, & Hendrik Schulze‐Koops. (2011). The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study: Commentary. 9(2). 1 indexed citations
7.
Huizinga, T., Peter A. Nigrović, Eric Ruderman, & Hendrik Schulze‐Koops. (2011). Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients: Commentary. 9(3). 1 indexed citations
8.
Huizinga, T., Peter A. Nigrović, Eric Ruderman, & Hendrik Schulze‐Koops. (2011). No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: Results from a longitudinal comparative MRI, ultrasonography, CT and radiography study - Commentary. 9(2). 68–69. 1 indexed citations
9.
Huizinga, T., Peter A. Nigrović, Eric Ruderman, & Hendrik Schulze‐Koops. (2011). The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept: Commentary. 9(2). 1 indexed citations
10.
Huizinga, T., Peter A. Nigrović, Eric Ruderman, & Hendrik Schulze‐Koops. (2011). Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway: Commentary. 9(3). 103–104. 2 indexed citations
11.
Huizinga, T., Peter A. Nigrović, Eric Ruderman, & Hendrik Schulze‐Koops. (2011). Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): A 48- week randomised controlled trial - Commentary. 9(3).
12.
Huizinga, T., Peter A. Nigrović, Eric Ruderman, & Hendrik Schulze‐Koops. (2011). Th17 cells expressing KIR3DL2 + and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis: Commentary. 9(2). 72–73. 2 indexed citations
13.
Huizinga, T., Peter A. Nigrović, Eric Ruderman, & Hendrik Schulze‐Koops. (2011). Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: Exploratory analyses from the BeSt study - Commentary. 9(2). 64–65. 1 indexed citations
14.
Huizinga, T., Peter A. Nigrović, Eric Ruderman, & Hendrik Schulze‐Koops. (2011). Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: Results of the ESTHER trial at week 48 - Commentary. 9(4).
15.
Huizinga, T., Peter A. Nigrović, Eric Ruderman, & Hendrik Schulze‐Koops. (2010). A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: The HEEL trial - Commentary. 8(4). 145–146. 1 indexed citations
16.
17.
Burmester, Gerd R, Patrick Durez, Eric Ruderman, et al.. (2006). Oral glucocorticoids have no impact on the efficacy or safety profile of rituximab in rheumatoid arthritis patients with inadequate response to TNF inhibitors (REFLEX study). Annals of the Rheumatic Diseases. 65. 180–180. 5 indexed citations
18.
Mease, Philip J., Dafna D. Gladman, Christopher T. Ritchlin, et al.. (2005). Clinical efficacy and safety of adalimumab for psoriatic arthritis: 48-week results of ADEPT. Research Portal (King's College London). 52(9). 2 indexed citations
19.
Mease, Philip J., Dafna D. Gladman, Christopher T. Ritchlin, et al.. (2004). Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study. Research Portal (King's College London). 50(12). 4097–4097. 19 indexed citations
20.
Ruderman, Eric, et al.. (2000). A PHASE III TRIAL OF ETANERCEPT vs METHOTREXATE (MTX) IN EARLY RHEUMATOID ARTHRITIS (ENBREL ERA TRIAL). 40(2). 229. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mitsumasa Kishimoto Breakdown of academic impact, for papers by Andrew J.K. Östör Breakdown of academic impact, for papers by Philippe Gaudin Breakdown of academic impact, for papers by Ennio Giulio Favalli Breakdown of academic impact, for papers by Frank Behrens Breakdown of academic impact, for papers by Joung-Liang Lan Breakdown of academic impact, for papers by Patrick Verschueren Breakdown of academic impact, for papers by Jeffrey D. Greenberg Breakdown of academic impact, for papers by C. Daïen Breakdown of academic impact, for papers by Elena Myasoedova
Rankless by CCL
2026